The Need for a 340B Uninsured Prescription Discount Card Program

SPONSORED CONTENT

Hospitals, community health centers and other covered entities participating in the 340B program are not-for-profit and the purpose of 340B is to help them stretch their scarce federal resource dollars to enhance patient care. The mission of covered entities (CEs) participating in this vital program is to provide healthcare services to everyone regardless of ability to pay. The need to optimize 340B savings is greater now more than ever, considering the current environment of manufacturers’ constraints.

Technology solutions to support these programs can help FQHC’s use the 340B program efficiently and effectively to engage their most vulnerable patients by passing on 340B savings to their uninsured and underinsured patients.

SUNRx recently hosted a webinar and panel discussion with subject matter experts that provided operational, strategic, and advocacy with insights for FQHC’s to consider when developing a 340B Prescription Discount Card strategy.

This webinar covered:

  • The value of real-time 340B eligibility
Read More »

Merck Becomes Eighth Drug Maker to Sue HRSA in Defense of 340B Contract Pharmacy Restrictions

Merck flag with flag of the United States of America
Merck is the eighth drug manufacturer to sue HRSA in defense of conditions on 340B pricing when covered entities use contract pharmacies.

Drug manufacturer Merck sued the federal government on Friday over the government’s May 6 letter telling the company its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal. The government warned Merck it could be

Read More »

PhRMA and J&J File Amicus Briefs in Support of Novartis and United Therapeutics

U.S. District Judge Dabney Friedrich seated at a hearing
PhRMA and Johnson & Johnson filed briefs backing Novartis and United Therapeutics's appeals of U.S. District Judge Dabney Friedrich’s ruling in their 340B contract pharmacy lawsuits.

Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that

Read More »

Senate Democratic Drug Pricing Bill Buoyed by Large Savings Estimate

Congressional Budget Office logo
U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over a decade, the CBO says.

U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over 10 years, the nonpartisan Congressional Budget Office said late last week.

Last November, CBO estimated that drug pricing language in the House-passed Build Back

Read More »

340B Hospital Annual Recertification Begins Aug. 27

A red Certified stamp
Annual recertification of 340B eligibility for hospitals starts Aug. 24 and ends Sept. 19.

Hospitals enrolled in the 340B program will have to recertify their eligibility for reduced 340B drug pricing this year between Aug. 24 and Sept. 19, the U.S. Health Resources and Services Administration says.

340B covered entities must annually recertify their

Read More »

3 Most Common Ways 340B Referral Savings Are Missed

Don Holladay headshot

SPONSORED CONTENT

Referral prescriptions can be a critical source of 340B savings opportunity for covered entities (CEs) in their mission to “…stretch federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” Whereas only a few years ago CEs were reluctant to engage in referral prescription opportunities due to compliance concerns, many have since added referral prescription capture to their 340B programs and become more confident in how they have created additional value for their program.

Maintaining data integrity across all the partners that support a 340B program is a top priority for covered entities, which poses a risk for both noncompliance and variances in value performance if data about patients and/or providers becomes inconsistent or changes structure. The following are three key considerations to look for when analyzing potential opportunity in referral prescription capture.

1. The Right Contract Pharmacy

Contract pharmacies are an effective extension of

Read More »

Analysts Still Digesting Senate Democratic Drug Pricing Bill’s 340B Changes

digital image of hand holding cash and hand holding pharmaceuticals
Covered entities are studying how a new drug pricing bill would affect access to 340B pricing on drugs subject to Medicare price negotiation.

If Congress votes to gives Medicare the power to negotiate some drug prices, drug manufacturers would not have to provide price concessions that exceed the lower of a drug’s 340B price or the Medicare negotiated price, according to a summary

Read More »

Appropriations Committee Passes Spending Bill with Increase in OPA Funding and Call to Action on Manufacturer Restrictions

Dept. of Health and Human Services exterior office sign and building
HRSA's Office of Pharmacy Affairs would get $13.2 million in fiscal year 2023 under a bill the House Appropriations Committee passed last week.

The U.S. Office of Pharmacy Affairs (OPA), the department within the U.S Health and Resources Administration that oversees the 340B program, would receive a $2 million increase in funding under a bill that passed through a major House committee last

Read More »

View from Capitol Hill Luncheon: Get the Latest Developments in the Ever-Changing 340B Program

Image of lunch roundtable speakers

SPONSORED CONTENT

Are you attending the upcoming 340B Coalition Summer Conference in Washington DC? Join us for Lunch!

Gaylord National Harbor

Monday, August 1 | 11:30 a.m. ET

Join some of the most respected 340B veterans for an interactive panel discussion on the latest updates impacting the 340B program.  Marsha Simon, Ph.D. and William von Oehsen helped to draft the original 340B legislation 30 years ago, and they’ll share their perspective on the evolution of the program and what’s next.  You will also hear from other 340B experts including Ted Slafsky of 340B Report and Cathy White of Cone Health.

This session will provide insights into:

  • How the 340B program has evolved over the last 30 years
  • What the Supreme Court’s decision on Medicare Part B cuts means for 340B hospitals
  • The latest developments on Capitol Hill and the Administration
  • Growing momentum at the state and federal levels for 340B protections
  • Ways you can take action to protect 340B

This influential event is the go-to place to

Read More »

100 Congressional Democrats Urge HHS to Use Existing Power to Lower Drug Prices

soldiers marching in formation on parade ground
Congressional Democrats want HHS to use march-in rights and other existing authority to lower drug prices.

The U.S. Department of Health and Human Services should swiftly use its existing statutory authority—including forcing drug patent owners to license their products to others—to lower drug prices, 100 Democratic members of Congress urged HHS Secretary Xavier Becerra late last

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report